Abstract
The Breast Imaging Reporting and Data System (BI-RADS) category 3 assessment is used for breast imaging findings considered "probably benign," with less than a 2% likelihood of malignancy. It is used to increase specificity by decreasing the number of breast biopsies. It has been validated for mammography, breast US, and emerging indications for use in contrast-enhanced breast MRI. Despite the long-term use of category 3 and numerous published studies that evaluate characteristic imaging findings appropriate for this category, there is still misuse and confusion regarding its accurate use. Imaging findings classified as category 3 require short-term follow-up to assess stability and identify changes that may warrant a biopsy for early diagnosis of breast cancer. Category 3 should not be used in a screening study without a comprehensive diagnostic evaluation that may reveal suspicious features or downgrade a finding to benign. In mammography, category 3 findings are validated for grouped round calcifications, oval circumscribed masses, and nonpalpable asymmetries. In US, category 3 can be applied to oval circumscribed parallel solid masses and complicated cysts. Category 3 can be assigned to clustered microcysts when they are very small or deep in the breast. Recent studies have yielded characteristic findings appropriate for MRI category 3 that are expected to be included in the sixth edition of the BI-RADS atlas. These include oval circumscribed masses with associated T2-hyperintense signal, focal non-mass enhancement, and foci of enhancement with associated T 2-hyperintense signal. Surveillance with short-interval imaging enables radiologists to monitor findings and act early when a change is detected. ©RSNA, 2024 Supplemental material is available for this article. See the invited commentary by Cohen and Leung.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call